Clinical safety and efficacy of salvage reirradiation for upper abdominal malignancies

  • Jason Joon Bock Lee
  • Seo Hee Choi
  • Jung Ho Im
  • Jinsil SeongEmail author
Original Article



Reirradiation has the potential to provide effective local control of upper abdominal malignancies. This study aimed to evaluate the safety and efficacy of reirradiation for upper abdominal malignancies.


A total of 42 patients with a history of prior radiotherapy (RT) received reirradiation for abdominal malignancies between 2005 and 2017. Each patient’s medical records, contours, and dose distribution for both RT courses were reviewed. The median dose of the prior RT was 50.0 Gy (range, 30.0–60.0 Gy) and the median dose of reirradiation was 45.0 Gy (range, 15.0–75.0 Gy).


With a median follow-up of 10.9 months, the median infield-failure-free survival (IFFS) rate was 9.2 months. Gross tumor volume (GTV) significantly related to IFFS in both the univariate (p = 0.009) and multivariate analyses (p = 0.024), and patients with a GTV of <60.0 mL had an improved IFFS (p = 0.001). Four patients experienced ≥grade 3 late toxicities. In the retrospective dose reconstruction analysis in these patients, the cumulative dose to the most exposed 2 cc (D2cc) of the duodenum was >60.0 Gy (range, 60.1–73.7 Gy). In the univariate analysis, the D2cc of the duodenum and a preexisting duodenal ulcer identified using endoscopy prior to reirradiation significantly correlated with late severe toxicity (p = 0.021 and 0.017, respectively).


Reirradiation for upper abdominal malignancies could be safely performed for patients without preexisting gastrointestinal morbidity unless the duodenum received excessive radiation doses. Reirradiation could also provide substantial IFFS, especially for patients with a GTV of <60.0 mL.


Local control Toxicity Duodenum Gross tumor volume Radiotherapy dosage 

Klinische Sicherheit und Wirksamkeit der Salvage-Rebestrahlung bei bösartigen Tumoren im oberen Abdominalbereich



Eine Rebestrahlung hat das Potenzial, bösartige Tumore im oberen Abdominalbereich lokal zu kontrollieren. Diese Studie dient dem Zweck, festzustellen, ob eine Rebestrahlung in diesem Bereich sicher und effizient ist.


Insgesamt 42 Patienten mit einer Vorgeschichte von Bestrahlungen erhielten zwischen 2005 und 2017 eine Rebestrahlung für bösartige Tumore im oberen Abdominalbereich. Die medizinische Krankenakte, die Umrisse der Tumore und die Bestrahlungsdosen von beiden Behandlungen wurden bewertet. Der Mittelwert der ersten Bestrahlung lag bei 50,0 Gy (Spanne 30,0–60,0 Gy), der Mittelwert der Rebestrahlung betrug 45,0 Gy (Spanne 15,0–75,0 Gy).


Mit einer Durchschnittszeit von 10,9 Monaten lag die Durchschnittsrate des Infield-Failure-Free-Bereichs (IFFS) bei 9,2 Monaten. Das Gesamtvolumen des Tumors (GTV) zeigte große Wirkung in Verbindung mit IFFS, in der univariaten (p = 0,009) sowie in der multivariaten Analyse (p = 0,024). Patienten mit einem GTV von <60,0 ml hatten einen verbesserten IFFS (p = 0,001). Vier Patienten erlitten im Verlauf eine verzögerte Toxizität ≥Grad 3. Bei der retrospektiven Analyse der Dosen dieser Patienten stellte sich heraus, dass die kumulative Dosis der am meisten exponierten 2 cc (D2cc) des Duodenums >60,0 Gy betrug (Spanne 60,1–73,7 Gy). In der univariaten Analyse zeigte sich, dass der D2cc-Gehalt des Duodenums und ein prädisponierter Duodenalulkus, der vor der Rebestrahlung mittels Endoskopie identifiziert wurde, direkt mit einer verzögerten Toxizität (jeweils p = 0,021 bzw. 0,017) in Verbindung gebracht werden konnte.


Eine Rebestrahlung bei bösartigen Tumoren im oberen Abdominalbereich kann bei Patienten, bei denen keine prädisponierte gastrointestinale Erkrankung vorliegt, sicher durchgeführt werden, es sei denn, das Duodenum erhielt exzessive Bestrahlungsdosen. Rebestrahlung kann zudem auch erheblich zu IFFS beitragen, vor allem bei Patienten mit einem GTV von <60,0 ml.


Lokale Kontrolle Toxizität Duodenum Gesamtvolumen des Tumors Bestrahlungsdosis 


Compliance with ethical guidelines

Conflict of interest

J.J.B. Lee, S.H. Choi, J.H. Im, and J. Seong declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

66_2018_1420_MOESM1_ESM.pdf (121 kb)
Supplementary tables with details of adverse events, characteristics of patients with severe late toxicites, and results of subgroup analyses of long-term survivors


  1. 1.
    Garg AK, Wang XS, Shiu AS, Allen P, Yang J, McAleer MF et al (2011) Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience. Cancer 117:3509–3516CrossRefGoogle Scholar
  2. 2.
    Medin PM, Foster RD, van der Kogel AJ, Sayre JW, McBride WH, Solberg TD (2012) Spinal cord tolerance to reirradiation with single-fraction radiosurgery: a swine model. Int J Radiat Oncol Biol Phys 83:1031–1037CrossRefGoogle Scholar
  3. 3.
    Lee N, Chan K, Bekelman JE, Zhung J, Mechalakos J, Narayana A et al (2007) Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 68:731–740CrossRefGoogle Scholar
  4. 4.
    Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA (2011) Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 80:669–676CrossRefGoogle Scholar
  5. 5.
    Popovtzer A, Gluck I, Chepeha DB, Teknos TN, Moyer JS, Prince ME et al (2009) The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 74:1342–1347CrossRefGoogle Scholar
  6. 6.
    Guren MG, Undseth C, Rekstad BL, Braendengen M, Dueland S, Spindler KL et al (2014) Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol 113:151–157CrossRefGoogle Scholar
  7. 7.
    Kamran SC, Harshman LC, Bhagwat MS, Muralidhar V, Nguyen PL, Martin NE et al (2017) Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: a high-volume cancer center experience. Adv Radiat Oncol 2:140–147CrossRefGoogle Scholar
  8. 8.
    Yamazaki H, Demizu Y, Okimoto T, Ogita M, Himei K, Nakamura S et al (2017) Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy. Strahlenther Onkol 193:525–533CrossRefGoogle Scholar
  9. 9.
    Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W et al (2008) Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 30:281–288CrossRefGoogle Scholar
  10. 10.
    Duprez F, Madani I, Bonte K, Boterberg T, Vakaet L, Derie C et al (2009) Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol 93:563–569CrossRefGoogle Scholar
  11. 11.
    Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M et al (2013) Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 85:e143–e149CrossRefGoogle Scholar
  12. 12.
    Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK et al (2010) Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 76:S101–S107CrossRefGoogle Scholar
  13. 13.
    Cheng JC, Wu JK, Huang CM, Huang DY, Cheng SH, Lin YM et al (2002) Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 63:41–45CrossRefGoogle Scholar
  14. 14.
    Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR et al (2009) Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol 4:55CrossRefGoogle Scholar
  15. 15.
    Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR et al (2013) Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol 4:343–351Google Scholar
  16. 16.
    Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A et al (2016) Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer. J Cancer 7:283–288CrossRefGoogle Scholar
  17. 17.
    Seol SW, Yu JI, Park HC, Lim DH, Oh D, Noh JM et al (2015) Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J 33:276–283CrossRefGoogle Scholar
  18. 18.
    Verma J, Sulman EP, Jhingran A, Tucker SL, Rauch GM, Eifel PJ et al (2014) Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 88:357–362CrossRefGoogle Scholar
  19. 19.
    Yoon H, Oh D, Park HC, Kang SW, Han Y, Lim DH et al (2013) Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma. Strahlenther Onkol 189:541–546CrossRefGoogle Scholar
  20. 20.
    Olteanu LA, Madani I, De Neve W, Vercauteren T, De Gersem W (2012) Evaluation of deformable image coregistration in adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys 83:696–703CrossRefGoogle Scholar
  21. 21.
    Lee DS, Woo JY, Kim JW, Seong J (2016) Re-irradiation of hepatocellular carcinoma: clinical applicability of deformable image registration. Yonsei Med J 57:41–49CrossRefGoogle Scholar
  22. 22.
    Hajj C, Goodman KA (2015) Role of radiotherapy and newer techniques in the treatment of GI cancers. J Clin Oncol 33:1737–1744CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation Oncology, Yonsei Cancer CenterYonsei University College of MedicineSeoulKorea (Republic of)

Personalised recommendations